TheEdgeResearch
Home / Stocks / LNAI

Lunai Bioworks Inc. (LNAI)

NASDAQ Healthcare Biotechnology
$1.93 ▼ -0.52%
Market Cap
$8.8M
Sector
Healthcare
Industry
Biotechnology
Beta
0.34
52-Wk Range
1.208-13.28
CEO
David H. Weinstein
Country
US
Currency
USD

Lunai Bioworks Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Los Angeles, CA, US. The stock last traded at $1.93, down 0.52% on the session, giving a market capitalisation of $8.8M. On trailing twelve-month figures it carries a trailing P/E of -0.03, a net margin of -612568.1%. Its beta of 0.34 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.03
Price / Sales
417.84
Price / Book
-0.63
EV / EBITDA
-0.05
Gross margin
-360.7%
Operating margin
-46992.0%
Net margin
-612568.1%
Return on equity
—
Debt / equity
-0.15
Current ratio
0.19
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
29
IPO date
2025-09-30
Headquarters
Los Angeles, CA, US
About Lunai Bioworks Inc.

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."

Comparable companies

Lunai Bioworks Inc. is most often compared with the following Healthcare names:

ADAPANLAPLMBLRXERNAGOVXICULPCNMBRXTHAR
More research on LNAI
LNAI technical analysis LNAI TheEdge Score Compare against peers
Open full interactive analysis & DCF →